Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions
Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away fr...
Gespeichert in:
Veröffentlicht in: | Molecular psychiatry 2020-11, Vol.25 (11), p.2742-2758 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2758 |
---|---|
container_issue | 11 |
container_start_page | 2742 |
container_title | Molecular psychiatry |
container_volume | 25 |
creator | Hare, Brendan D. Duman, Ronald S. |
description | Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities. |
doi_str_mv | 10.1038/s41380-020-0685-9 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7442605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639117945</galeid><sourcerecordid>A639117945</sourcerecordid><originalsourceid>FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</originalsourceid><addsrcrecordid>eNp1Ul1v1iAUJkbj5vQHeGOaeONNN6CUFi9MlkWnyRKXxXvCC6eVpS9UoMv27z313ea2aAiB8HzAOTyEvGX0kNGmP8qCNT2tKccp-7ZWz8g-E52s27brn-O-aVUtWC_2yKucLyldwfYl2Ws47aVoxD65Ok8wpBiKmSobU4HryvpkF19y5UPlYE6Qs4-hMsHhvPZQbj4iNZTkN0tZkThUzmeboEAVYEE3NJvjvExmxfMfaTFphFIlGNej1-TFYKYMb27XA3Lx5fOPk6_12ffTbyfHZ7WVtCm14YMQTjHhOsaglbzDZwMwYTjvsJRWCrMRDqwRYNig-sEpZzpQUkrbHJBPO9N52WzBWcA3m0nPyW9NutHReP0YCf6nHuOV7oTgkrZo8OHWIMVfC-Sit1gnTJMJEJeseSM5Va2iEqnvn1Av45KwEcgSHROKse4BazQTaB-GiPfa1VQfy2blKLFee_gPFg4HW4-dh8Hj-SMB2wlsijnjh97XyKhek6J3SdGYFL0mRSvUvHvYnHvFXTSQwHeEjFAYIf2t6P-uvwHIiMso</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471491176</pqid></control><display><type>article</type><title>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Hare, Brendan D. ; Duman, Ronald S.</creator><creatorcontrib>Hare, Brendan D. ; Duman, Ronald S.</creatorcontrib><description>Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-020-0685-9</identifier><identifier>PMID: 32086434</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/378 ; 692/699/476/1414 ; Antidepressants ; Antidepressive Agents - pharmacology ; Antidepressive Agents - therapeutic use ; Anxiety ; Anxiety - drug therapy ; Anxiety - pathology ; Behavioral Sciences ; Biological Psychology ; Brain ; Depression - drug therapy ; Depression - pathology ; Depression, Mental ; Ketamine ; Ketamine - pharmacology ; Ketamine - therapeutic use ; Magnetic fields ; Medicine ; Medicine & Public Health ; Mental depression ; Neural Pathways - drug effects ; Neurons ; Neurosciences ; Pharmacotherapy ; Prefrontal cortex ; Prefrontal Cortex - drug effects ; Prefrontal Cortex - pathology ; Psychiatry ; Review Article ; Transcranial magnetic stimulation</subject><ispartof>Molecular psychiatry, 2020-11, Vol.25 (11), p.2742-2758</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</citedby><cites>FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</cites><orcidid>0000-0001-8690-8439 ; 0000-0002-6502-3188</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41380-020-0685-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41380-020-0685-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32086434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hare, Brendan D.</creatorcontrib><creatorcontrib>Duman, Ronald S.</creatorcontrib><title>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.</description><subject>631/378</subject><subject>692/699/476/1414</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Anxiety</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - pathology</subject><subject>Behavioral Sciences</subject><subject>Biological Psychology</subject><subject>Brain</subject><subject>Depression - drug therapy</subject><subject>Depression - pathology</subject><subject>Depression, Mental</subject><subject>Ketamine</subject><subject>Ketamine - pharmacology</subject><subject>Ketamine - therapeutic use</subject><subject>Magnetic fields</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mental depression</subject><subject>Neural Pathways - drug effects</subject><subject>Neurons</subject><subject>Neurosciences</subject><subject>Pharmacotherapy</subject><subject>Prefrontal cortex</subject><subject>Prefrontal Cortex - drug effects</subject><subject>Prefrontal Cortex - pathology</subject><subject>Psychiatry</subject><subject>Review Article</subject><subject>Transcranial magnetic stimulation</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1Ul1v1iAUJkbj5vQHeGOaeONNN6CUFi9MlkWnyRKXxXvCC6eVpS9UoMv27z313ea2aAiB8HzAOTyEvGX0kNGmP8qCNT2tKccp-7ZWz8g-E52s27brn-O-aVUtWC_2yKucLyldwfYl2Ws47aVoxD65Ok8wpBiKmSobU4HryvpkF19y5UPlYE6Qs4-hMsHhvPZQbj4iNZTkN0tZkThUzmeboEAVYEE3NJvjvExmxfMfaTFphFIlGNej1-TFYKYMb27XA3Lx5fOPk6_12ffTbyfHZ7WVtCm14YMQTjHhOsaglbzDZwMwYTjvsJRWCrMRDqwRYNig-sEpZzpQUkrbHJBPO9N52WzBWcA3m0nPyW9NutHReP0YCf6nHuOV7oTgkrZo8OHWIMVfC-Sit1gnTJMJEJeseSM5Va2iEqnvn1Av45KwEcgSHROKse4BazQTaB-GiPfa1VQfy2blKLFee_gPFg4HW4-dh8Hj-SMB2wlsijnjh97XyKhek6J3SdGYFL0mRSvUvHvYnHvFXTSQwHeEjFAYIf2t6P-uvwHIiMso</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Hare, Brendan D.</creator><creator>Duman, Ronald S.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8690-8439</orcidid><orcidid>https://orcid.org/0000-0002-6502-3188</orcidid></search><sort><creationdate>20201101</creationdate><title>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</title><author>Hare, Brendan D. ; Duman, Ronald S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c603t-a2f44d914d711e5627864ee14a227765564ab4deca4ea1f98fd9da7e9666c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/378</topic><topic>692/699/476/1414</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Anxiety</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - pathology</topic><topic>Behavioral Sciences</topic><topic>Biological Psychology</topic><topic>Brain</topic><topic>Depression - drug therapy</topic><topic>Depression - pathology</topic><topic>Depression, Mental</topic><topic>Ketamine</topic><topic>Ketamine - pharmacology</topic><topic>Ketamine - therapeutic use</topic><topic>Magnetic fields</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mental depression</topic><topic>Neural Pathways - drug effects</topic><topic>Neurons</topic><topic>Neurosciences</topic><topic>Pharmacotherapy</topic><topic>Prefrontal cortex</topic><topic>Prefrontal Cortex - drug effects</topic><topic>Prefrontal Cortex - pathology</topic><topic>Psychiatry</topic><topic>Review Article</topic><topic>Transcranial magnetic stimulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hare, Brendan D.</creatorcontrib><creatorcontrib>Duman, Ronald S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hare, Brendan D.</au><au>Duman, Ronald S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>25</volume><issue>11</issue><spage>2742</spage><epage>2758</epage><pages>2742-2758</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes. This work has resulted in a paradigm shift away from dysregulation of single neurotransmitter systems in depression towards circuit level abnormalities impacting function across multiple brain regions and neurotransmitter systems. Studies on the features of circuit level abnormalities demonstrate structural changes within the prefrontal cortex (PFC) and functional changes in its communication with distal brain structures. Treatments that impact the activity of brain regions, such as transcranial magnetic stimulation or rapid-acting antidepressants like ketamine, appear to reverse depression associated circuit abnormalities though the mechanisms underlying the reversal, as well as development of these abnormalities remains unclear. Recently developed optogenetic and chemogenetic tools that allow high-fidelity control of neuronal activity in preclinical models have begun to elucidate the contributions of the PFC and its circuitry to depression- and anxiety-like behavior. These tools offer unprecedented access to specific circuits and neuronal subpopulations that promise to offer a refined view of the circuit mechanisms surrounding depression and potential mechanistic targets for development and reversal of depression associated circuit abnormalities.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32086434</pmid><doi>10.1038/s41380-020-0685-9</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-8690-8439</orcidid><orcidid>https://orcid.org/0000-0002-6502-3188</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-4184 |
ispartof | Molecular psychiatry, 2020-11, Vol.25 (11), p.2742-2758 |
issn | 1359-4184 1476-5578 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7442605 |
source | MEDLINE; SpringerLink Journals |
subjects | 631/378 692/699/476/1414 Antidepressants Antidepressive Agents - pharmacology Antidepressive Agents - therapeutic use Anxiety Anxiety - drug therapy Anxiety - pathology Behavioral Sciences Biological Psychology Brain Depression - drug therapy Depression - pathology Depression, Mental Ketamine Ketamine - pharmacology Ketamine - therapeutic use Magnetic fields Medicine Medicine & Public Health Mental depression Neural Pathways - drug effects Neurons Neurosciences Pharmacotherapy Prefrontal cortex Prefrontal Cortex - drug effects Prefrontal Cortex - pathology Psychiatry Review Article Transcranial magnetic stimulation |
title | Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prefrontal%20cortex%20circuits%20in%20depression%20and%20anxiety:%20contribution%20of%20discrete%20neuronal%20populations%20and%20target%20regions&rft.jtitle=Molecular%20psychiatry&rft.au=Hare,%20Brendan%20D.&rft.date=2020-11-01&rft.volume=25&rft.issue=11&rft.spage=2742&rft.epage=2758&rft.pages=2742-2758&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-020-0685-9&rft_dat=%3Cgale_pubme%3EA639117945%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471491176&rft_id=info:pmid/32086434&rft_galeid=A639117945&rfr_iscdi=true |